Evidence map›Paper›PMID 33837453›Full record

ReviewAbdominal radiology (New York)2021

Frontiers of therapy for hepatocellular carcinoma.

Michael Heller, Neehar D Parikh, Nicholas Fidelman, Dawn Owen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. LncRNA model predicts liver cancer drug resistance and validateFrontiers in cell and developmental biology · 2023
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael HellerDepartment of Interventional Radiology, University of California San Francisco, 505 Parnassus Avenue, M-361, San Francisco, CA, 94143, USA. Michael.Heller@UCSF.edu.ORCID http://orcid.org/0000-0003-2492-880X
Neehar D ParikhDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA.
Nicholas FidelmanDepartment of Interventional Radiology, University of California San Francisco, 505 Parnassus Avenue, M-361, San Francisco, CA, 94143, USA.
Dawn OwenDepartment of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of hepatocellular carcinoma continues to increase worldwide. Fortunately, there have been notable recent advances in locoregional and systemic therapy. In this current review, we will highlight these new developments and future directions of hepatocellular carcinoma treatment and address the importance of a multidisciplinary approach to treatment.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansHepatocellular CarcinomaOncologyRadiation therapySystemic therapyTransarterial radioembolization

Identifiers

PMID33837453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.